Rexahn Pharmaceuticals, Inc.

( )
REXN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. -3.94%74.671.0%$1808.50m
AMGNAmgen, Inc. -1.32%208.781.3%$898.33m
REGNRegeneron Pharmaceuticals, Inc. -0.55%501.512.6%$832.58m
BIIBBiogen, Inc. -3.27%301.211.5%$768.55m
VRTXVertex Pharmaceuticals, Inc. -2.99%247.671.9%$644.24m
MRNAModerna, Inc. -7.56%32.020.0%$518.77m
ILMNIllumina, Inc. 0.95%280.643.5%$494.32m
ALXNAlexion Pharmaceuticals, Inc. -1.24%94.722.0%$299.75m
AAgilent Technologies, Inc. -0.46%74.021.6%$226.92m
INCYIncyte Corp. 1.82%86.662.5%$218.22m
EXASEXACT Sciences Corp. 0.53%62.6021.0%$178.66m
SGENSeattle Genetics, Inc. -2.09%121.876.1%$164.60m
BMRNBioMarin Pharmaceutical, Inc. -3.55%79.834.3%$153.92m
IMMUImmunomedics, Inc. 0.69%18.9111.9%$120.80m
NVAXNovavax, Inc. -7.45%14.90114.7%$113.95m

Company Profile

Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.